Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Number of holders
-
47
-
Total 13F shares, excl. options
-
31,884,613
-
Shares change
-
-120,986
-
Total reported value, excl. options
-
$259,855,000
-
Value change
-
-$981,225
-
Number of buys
-
15
-
Number of sells
-
20
-
Price
-
$8.15
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q2 2016
As of 30 Jun 2016 Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) had 47 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 31,884,613 shares of stock of the company.
Largest 10 holders included NEA Management Company, LLC, FMR LLC, Capital World Investors, ADAGE CAPITAL PARTNERS GP, L.L.C., Foresite Capital Management II, LLC, QVT Financial LP, Rock Springs Capital Management LP, FIL Ltd, ORBIMED ADVISORS LLC, and MILLENNIUM MANAGEMENT LLC.
This table shows 47 institutional shareholders of the security as of 30 Jun 2016.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.